Business Description
Altamira Therapeutics Ltd
NAICS : 541714
SIC : 2834
ISIN : CH0408330303
Total Employee Number:
13Description
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 76.4 | |||||
3-Year EPS without NRI Growth Rate | 77 | |||||
3-Year FCF Growth Rate | 84.3 | |||||
3-Year Book Growth Rate | -84.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.11 | |||||
Quick Ratio | 0.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -401.3 | |||||
Shareholder Yield % | -105.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -100.01 | |||||
ROA % | -71.1 | |||||
ROIC % | -74.65 | |||||
3-Year ROIIC % | -4.95 | |||||
ROC (Joel Greenblatt) % | -1294 | |||||
ROCE % | -87.78 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.07 | |||||
EV-to-EBIT | -0.19 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-FCF | -0.25 | |||||
Earnings Yield (Greenblatt) % | -526.32 | |||||
FCF Yield % | -1501.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altamira Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.109 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -34.93 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 948 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 948 - 948 | ||
| Shares Outstanding (Mil) | 5.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altamira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altamira Therapeutics Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2023-12-13 | 948.00 (+0.00%) | ||
| 0.05:1 Stock Split | 2022-10-25 | 948.00 (+0.00%) | ||
| 0.05:1 Stock Split | 2019-05-02 | 2,149.60 (+0.00%) |
Show
Entries
Altamira Therapeutics Ltd Frequently Asked Questions
What is Altamira Therapeutics Ltd(FRA:2QA)'s stock price today?
The current price of FRA:2QA is €948.00. The 52 week high of FRA:2QA is €948.00 and 52 week low is €948.00.
When is next earnings date of Altamira Therapeutics Ltd(FRA:2QA)?
The next earnings date of Altamira Therapeutics Ltd(FRA:2QA) is .
Does Altamira Therapeutics Ltd(FRA:2QA) pay dividends? If so, how much?
Altamira Therapeutics Ltd(FRA:2QA) does not pay dividend.
Press Release
Articles on Altamira Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers